Wedbush Has Weak Outlook for Replimune Group FY2025 Earnings

Replimune Group, Inc. (NASDAQ:REPL) – Equities researchers at Wedbush reduced their FY2025 earnings per share (EPS) estimates for Replimune Group in a research note issued on Wednesday, February 12th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($3.07) per share for the year, down from their prior estimate of ($2.91). The consensus estimate for Replimune Group’s current full-year earnings is ($2.88) per share. Wedbush also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.93) EPS.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09).

REPL has been the subject of a number of other research reports. HC Wainwright raised their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, February 13th. BMO Capital Markets lifted their target price on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Finally, Jefferies Financial Group boosted their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $19.29.

Replimune Group Trading Down 0.5 %

Shares of NASDAQ REPL opened at $14.03 on Monday. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a 50-day moving average of $12.57 and a two-hundred day moving average of $11.77. The company has a market cap of $959.93 million, a PE ratio of -4.60 and a beta of 1.30. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Insider Buying and Selling at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC grew its holdings in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after buying an additional 1,655 shares in the last quarter. Graham Capital Management L.P. grew its stake in shares of Replimune Group by 6.1% during the 4th quarter. Graham Capital Management L.P. now owns 30,180 shares of the company’s stock worth $365,000 after acquiring an additional 1,731 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Replimune Group by 7.2% in the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company’s stock valued at $456,000 after purchasing an additional 2,525 shares during the last quarter. Algert Global LLC lifted its position in shares of Replimune Group by 7.1% in the fourth quarter. Algert Global LLC now owns 45,820 shares of the company’s stock worth $555,000 after purchasing an additional 3,057 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Replimune Group by 24.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock worth $198,000 after purchasing an additional 3,177 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.